Peng Lu Sells 15,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) President Peng Lu sold 15,000 shares of Pharvaris stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $40.68, for a total transaction of $610,200.00. Following the completion of the transaction, the president directly owned 65,179 shares in the company, valued at approximately $2,651,481.72. The trade was a 18.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Peng Lu also recently made the following trade(s):

• On Thursday, June 18th, Peng Lu sold 300 shares of Pharvaris stock. The shares were sold at an average price of $34.00, for a total transaction of $10,200.00.

Pharvaris Stock Down 0.6%

Shares of PHVS opened at $37.51 on Friday. The stock has a market capitalization of $2.45 billion, a P/E ratio of -12.30 and a beta of -2.33. The firm has a fifty day simple moving average of $35.01 and a two-hundred day simple moving average of $31.34. Pharvaris N.V. has a twelve month low of $20.65 and a twelve month high of $43.25.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Sell-side analysts expect that Pharvaris N.V. will post -3.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Quantbot Technologies LP bought a new stake in shares of Pharvaris during the second quarter valued at approximately $41,000. JPMorgan Chase & Co. raised its holdings in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares in the last quarter. Barclays PLC purchased a new position in Pharvaris during the fourth quarter valued at $77,000. CoreCap Advisors LLC purchased a new position in Pharvaris during the second quarter valued at $93,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Pharvaris during the 4th quarter valued at $139,000.

Wall Street Analysts Forecast Growth

PHVS has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a report on Tuesday. Oppenheimer reissued an “outperform” rating and set a $75.00 target price on shares of Pharvaris in a research note on Tuesday. New Street Research set a $60.00 target price on Pharvaris in a report on Friday, August 14th. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a research note on Wednesday. Finally, Guggenheim lifted their price target on shares of Pharvaris from $40.00 to $44.00 and gave the company a “buy” rating in a report on Thursday. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $59.50.

Pharvaris News Roundup

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Analysts continued to support Pharvaris after positive Phase 3 data for extended-release deucrictibant in the CHAPTER-3 prophylaxis trial. The drug met its primary and secondary efficacy endpoints, strengthening the case for regulatory filings expected to begin in the first half of 2027.
• Positive Sentiment: RBC Capital reaffirmed its Buy/Outperform view and raised its price target to $62 from $52, citing the potential for deucrictibant XR to capture share in the hereditary angioedema market. RBC Capital rating
• Positive Sentiment: Citizens JMP increased its target to $79 from $75 and maintained a Market Outperform rating. HC Wainwright reiterated Buy with a $60 target, while Wedbush maintained Outperform. These actions reflect growing analyst confidence following Pharvaris’ Phase 3 progress.
• Positive Sentiment: Commentary highlighted Pharvaris’ potential to offer oral therapies for both on-demand treatment and prevention of hereditary angioedema attacks, which could improve its competitive positioning. Pharvaris HAE market opportunity
• Neutral Sentiment: The bullish outlook remains dependent on regulatory approval, successful commercialization and competition in the HAE market. Pharvaris is still a clinical-stage biotechnology company, and RBC continues to classify the stock as speculative.
• Negative Sentiment: President Peng Lu sold 15,000 shares for approximately $610,200, reducing his direct ownership by 18.71%. The sale may create a modest sentiment overhang, although it does not alter the company’s clinical results.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.